ASCO News: BioNTech and Pfizer’s bispecifics, and Pazdur — Day 2
Share
SHARE
Adam Feuerstein/STAT
Adam Feuerstein is a senior writer and biotech columnist, reporting on drug development, business, Wall Street, and biotechnology. He co-hosts the weekly biotech podcast The Readout Loud and writes the newsletter Adam’s Biotech Scorecard. Adam can be reached on Signal at stataf.54.
Matthew Herper covers medical innovation, focusing on both its potential and risks.
Angus reports on basic research, clinical science, and drug development with potential to improve patient survival and quality of life, alongside developments in the cancer community. He can be reached on Signal at angus.08.
Welcome to the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Subscribe for the email editions here.
Thanks to everyone who joined the packed STAT @ ASCO event last night. The bao buns were amazing. IYKYK.
Remember to register for our ASCO virtual recap on Wednesday.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Gain access to this article and more daily biotech coverage by subscribing to STAT+.
Already have an account? Log in
View All Plans
Subscribe to STAT+ to read the full story.
Subscribe
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He also co-hosts the weekly biotech podcast The Readout Loud and writes the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
Senior Writer, Medicine, Editorial Director of Events
Matthew Herper covers medical innovation — both its promise and its perils.
Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08.
